SIRs and EARs of SMs in the cohort compared with the age-, sex-, and calendar year–matched Alberta general population
| Risk factor . | Category . | Observed . | Expected . | SIR* (95% CI) . | P . | EAR† per 1000 person years . |
|---|---|---|---|---|---|---|
| Full cohort | 56 | 32 | 1.75 (1.32-2.28) | <.01 | 4.3 | |
| TBI | Yes | 23 | 16.3 | 1.41 (0.90-2.12) | .07 | 2.1 |
| No | 33 | 15.7 | 2.10 (1.45-2.96) | <.01 | 7.1 | |
| Age | ≤50 y | 24 | 10.4 | 2.31 (1.48-3.43) | <.01 | 3.7 |
| >50 y | 32 | 21.6 | 1.48 (1.02-2.10) | .02 | 5.5 | |
| Sex | Female | 19 | 12.7 | 1.50 (0.90-2.34) | .06 | 2.7 |
| Male | 37 | 19.3 | 1.92 (1.35-2.64) | <.01 | 5.5 | |
| cGVHD‡ | Yes | 30 | 13.2 | 2.28 (1.54-3.25) | <.01 | 7.9 |
| No | 26 | 18.8 | 1.38 (0.90-2.03) | .07 | 2.1 | |
| aGVHD§ | Yes | 17 | 6.1 | 2.78 (1.62-4.46) | <.01 | 9.4 |
| No | 39 | 25.7 | 1.52 (1.08-2.07) | .01 | 3.0 | |
| Stem cell source | PBSC | 49 | 27.3 | 1.79 (1.33-2.37) | <.01 | 4.6 |
| Other | 7 | 4.6 | 1.52 (0.61-3.14) | .18 | 2.7 | |
| Underlying disease | Acute leukemia | 17 | 14.2 | 1.20 (0.70-1.92) | .26 | 0.9 |
| Lymphoma/CLL | 22 | 8.1 | 2.72 (1.70-4.12) | <.01 | 13.8 | |
| MDS/MPN/other | 17 | 9.6 | 1.78 (1.04-2.85) | .02 | 5.3 |
| Risk factor . | Category . | Observed . | Expected . | SIR* (95% CI) . | P . | EAR† per 1000 person years . |
|---|---|---|---|---|---|---|
| Full cohort | 56 | 32 | 1.75 (1.32-2.28) | <.01 | 4.3 | |
| TBI | Yes | 23 | 16.3 | 1.41 (0.90-2.12) | .07 | 2.1 |
| No | 33 | 15.7 | 2.10 (1.45-2.96) | <.01 | 7.1 | |
| Age | ≤50 y | 24 | 10.4 | 2.31 (1.48-3.43) | <.01 | 3.7 |
| >50 y | 32 | 21.6 | 1.48 (1.02-2.10) | .02 | 5.5 | |
| Sex | Female | 19 | 12.7 | 1.50 (0.90-2.34) | .06 | 2.7 |
| Male | 37 | 19.3 | 1.92 (1.35-2.64) | <.01 | 5.5 | |
| cGVHD‡ | Yes | 30 | 13.2 | 2.28 (1.54-3.25) | <.01 | 7.9 |
| No | 26 | 18.8 | 1.38 (0.90-2.03) | .07 | 2.1 | |
| aGVHD§ | Yes | 17 | 6.1 | 2.78 (1.62-4.46) | <.01 | 9.4 |
| No | 39 | 25.7 | 1.52 (1.08-2.07) | .01 | 3.0 | |
| Stem cell source | PBSC | 49 | 27.3 | 1.79 (1.33-2.37) | <.01 | 4.6 |
| Other | 7 | 4.6 | 1.52 (0.61-3.14) | .18 | 2.7 | |
| Underlying disease | Acute leukemia | 17 | 14.2 | 1.20 (0.70-1.92) | .26 | 0.9 |
| Lymphoma/CLL | 22 | 8.1 | 2.72 (1.70-4.12) | <.01 | 13.8 | |
| MDS/MPN/other | 17 | 9.6 | 1.78 (1.04-2.85) | .02 | 5.3 |
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; PBSC, peripheral blood stem cell.
Observed cases/expected cases with expected cases derived from age-, sex-, and calendar year–matched Alberta general population rates.
Observed cases – expected cases, per 1000 person years.
Moderate to severe cGVHD.
Grades II to IV aGVHD.